BioWorld

May 13, 2002

ViroPharma Prepares To Receive Not Approvable' Picovir Letter

The FDA is not expected to grant ViroPharma Inc. regulatory clearance for its cold medicine that has been criticized for reducing the duration of illness by only one day. (BioWorld Today) Read More

Wyeth Stops Heart Attack Study; Neose Loses Manufacturing Deal

TIGR Deploys Sequence-Based Genomic Analyses To Compare Suspect Anthrax Strain Variants

Isotechnika, Roche To Focus On Transplantation; RA Trial Delayed

Other News To Note

Gliatech Files For Chapter 11 Following Product Setbacks

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...